Study ID: Sanofi Odyssey Outcomes Study

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome


The purpose of this study is to determine whether the study drug (SAR236553) might prevent future cardiovascular events (such as, heart attacks or strokes) in patients who have experienced a recent coronary event. The study will compare the study drug versus a placebo injection (an inactive solution injection) on the occurrence of future cardiovascular events such as heart attack and stroke, when given in addition to the standard of care for lowering cholesterol.

Fargo Region
Principal Investigator:
Thomas Haldis, DO
Phase IIIB


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list